MY186271A - Ophthalmic compositions and methods of use therefor - Google Patents
Ophthalmic compositions and methods of use thereforInfo
- Publication number
- MY186271A MY186271A MYPI2017703238A MYPI2017703238A MY186271A MY 186271 A MY186271 A MY 186271A MY PI2017703238 A MYPI2017703238 A MY PI2017703238A MY PI2017703238 A MYPI2017703238 A MY PI2017703238A MY 186271 A MY186271 A MY 186271A
- Authority
- MY
- Malaysia
- Prior art keywords
- methods
- ophthalmic compositions
- use therefor
- compositions
- conditions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Peptides Or Proteins (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Physiology (AREA)
- Botany (AREA)
- Developmental Biology & Embryology (AREA)
- Environmental Sciences (AREA)
- Eyeglasses (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ70572715 | 2015-03-05 | ||
| PCT/NZ2016/050033 WO2016140581A1 (en) | 2015-03-05 | 2016-03-04 | Ophthalmic compositions and methods of use therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY186271A true MY186271A (en) | 2021-07-01 |
Family
ID=56848288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2017703238A MY186271A (en) | 2015-03-05 | 2016-03-04 | Ophthalmic compositions and methods of use therefor |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10842850B2 (enExample) |
| EP (1) | EP3265096B9 (enExample) |
| JP (4) | JP2018513117A (enExample) |
| KR (1) | KR102450674B1 (enExample) |
| CN (1) | CN107530360B (enExample) |
| AU (1) | AU2016226699B2 (enExample) |
| ES (1) | ES2952700T3 (enExample) |
| MY (1) | MY186271A (enExample) |
| SG (1) | SG11201708114SA (enExample) |
| TW (1) | TWI747816B (enExample) |
| WO (1) | WO2016140581A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9622911B2 (en) | 2010-09-30 | 2017-04-18 | Cxl Ophthalmics, Llc | Ophthalmic treatment device, system, and method of use |
| EP4420725A3 (en) | 2012-03-29 | 2025-04-16 | Epion Therapeutics, Inc. | Ocular treatment solutions, delivery devices and delivery augmentation methods |
| US9566301B2 (en) | 2012-03-29 | 2017-02-14 | Cxl Ophthalmics, Llc | Compositions and methods for treating or preventing diseases associated with oxidative stress |
| TWI747816B (zh) * | 2015-03-05 | 2021-12-01 | 紐西蘭商奧克蘭聯合服務有限公司 | 眼用組合物用於製備藥物的用途 |
| WO2017015471A1 (en) | 2015-07-21 | 2017-01-26 | Avedro, Inc. | Systems and methods for treaments of an eye with a photosensitizer |
| CN110092816B (zh) * | 2018-01-29 | 2023-08-01 | 上海市第一人民医院 | 预防和治疗纤维化的小分子多肽及其应用 |
| US20210060017A1 (en) * | 2018-02-27 | 2021-03-04 | Shilpa Medicare Ltd | Methotrexate ophthalmic solution |
| CN108728418A (zh) * | 2018-06-19 | 2018-11-02 | 新乡医学院 | 一种鸡胚中枢神经系统单个神经元动态研究模型的制备方法及应用 |
| US11672860B2 (en) * | 2018-11-02 | 2023-06-13 | Senseonics, Incorporated | Drug eluting matrix on analyte indicator |
| GB201820021D0 (en) * | 2018-12-07 | 2019-01-23 | Univ Birmingham | Ocular hydrogel compositions |
| JP2022125941A (ja) * | 2021-02-17 | 2022-08-29 | 株式会社ティ・エム・ディ | コンタクトレンズ |
| WO2024206871A1 (en) * | 2023-03-30 | 2024-10-03 | Cetel Scientific Llc | Amniotic and chorionic collagen for ocular surface healing |
| KR20250092172A (ko) | 2022-09-01 | 2025-06-23 | 옵티파이 테라퓨틱스 아게 | 안과용 조성물 |
| US20240119865A1 (en) * | 2022-10-07 | 2024-04-11 | Life Model Designs LLC | Synthetic blood clot |
| CN121490062B (zh) * | 2026-01-12 | 2026-05-15 | 上饶爱尔眼科医院有限公司 | 含地塞米松的组合物及其在制备治疗视网膜病变的药物中的应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3786812A (en) * | 1972-03-10 | 1974-01-22 | C Neefe | Contact lens for olar drug delivery |
| US4177268A (en) | 1973-05-30 | 1979-12-04 | Jouveinal S.A. | Method of alleviating inflammation by administration of dexamethasone derivatives |
| US5124392A (en) * | 1988-10-03 | 1992-06-23 | Alcon Laboratories, Inc. | Pharmaceutical compositions and methods of treatment to prevent and treat corneal scar formation produced by laser irradiation |
| JPH06505965A (ja) * | 1990-11-16 | 1994-07-07 | セルトリックス ファーマシューティカルズ，インコーポレイテッド | β型トランスフォーミング成長因子 |
| US5411940A (en) * | 1993-09-29 | 1995-05-02 | Alcon Laboratories, Inc. | Use of TGF-β3 to reduce the formation of scar tissue in response to corneal trauma |
| NZ566132A (en) | 2003-02-13 | 2009-09-25 | Anthrogenesis Corp | Use of umbilical cord blood to treat inflammation, ParkinsonÆs disease or diabetes |
| MXPA03011987A (es) | 2003-12-19 | 2005-06-23 | Osio Sancho Alberto | Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal. |
| US20090232777A1 (en) * | 2006-03-01 | 2009-09-17 | Evy Lundgren-Akerlund | Expansion and Differentiation of Mesenchymal Stem Cells |
| GB0604938D0 (en) | 2006-03-11 | 2006-04-19 | Renovo Ltd | Proteins, nucleic acids and medicaments |
| US7767217B2 (en) | 2006-03-14 | 2010-08-03 | Foresight Biotherapeutics | Ophthalmic compositions comprising povidone-iodine |
| US8110655B2 (en) | 2006-11-13 | 2012-02-07 | Auxagen, Inc. | Method to promote hair growth and/or delay or treat hair loss by administering a TGF-β antagonist or inhibitor |
| RU2542471C2 (ru) | 2006-11-15 | 2015-02-20 | Коуда Терапьютикс, Инк. | Улучшенные способы и композиции для заживления ран |
| EP2229174A1 (en) | 2007-12-04 | 2010-09-22 | Novagali Pharma S.A. | Compositions comprising corticosteroid prodrug such as dexamethasone palmitate for the treatment of eye disorders |
| US7795316B1 (en) | 2007-12-19 | 2010-09-14 | Alcon Research, Ltd. | Topical ophthalmic compositions containing tobramycin and dexamethasone |
| CA2716390C (en) | 2008-02-25 | 2016-08-23 | Eyegate Pharma S.A.S. | Enhanced delivery of a therapeutic to ocular tissues through iontophoresis |
| EP2962682B1 (en) * | 2008-12-11 | 2018-03-28 | Massachusetts Institute Of Technology | Method of making a contact lens drug delivery device |
| US10201548B2 (en) | 2009-03-06 | 2019-02-12 | Sun Pharma Global Fze | Methods for treating ocular inflammatory diseases |
| WO2012088044A2 (en) * | 2010-12-20 | 2012-06-28 | James Mcmillan | Compositions and methods for improving ocular surface health, corneal clarity, optical function and maintaining visual acuity |
| US20130165419A1 (en) * | 2011-12-21 | 2013-06-27 | Insite Vision Incorporated | Combination anti-inflammatory ophthalmic compositions |
| KR101518370B1 (ko) | 2013-06-25 | 2015-05-07 | 가톨릭대학교 산학협력단 | Il-10 생성 조절 t세포로의 분화 유도용 조성물 |
| CN104548210A (zh) | 2014-12-13 | 2015-04-29 | 浙江大学 | 含地塞米松转化生长因子的可控缓释plga微球及制备 |
| TWI747816B (zh) | 2015-03-05 | 2021-12-01 | 紐西蘭商奧克蘭聯合服務有限公司 | 眼用組合物用於製備藥物的用途 |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
-
2016
- 2016-03-04 TW TW105106605A patent/TWI747816B/zh active
- 2016-03-04 MY MYPI2017703238A patent/MY186271A/en unknown
- 2016-03-04 SG SG11201708114SA patent/SG11201708114SA/en unknown
- 2016-03-04 US US15/555,909 patent/US10842850B2/en active Active
- 2016-03-04 JP JP2017546870A patent/JP2018513117A/ja active Pending
- 2016-03-04 ES ES16759200T patent/ES2952700T3/es active Active
- 2016-03-04 EP EP16759200.5A patent/EP3265096B9/en active Active
- 2016-03-04 AU AU2016226699A patent/AU2016226699B2/en active Active
- 2016-03-04 CN CN201680026065.0A patent/CN107530360B/zh active Active
- 2016-03-04 KR KR1020177028161A patent/KR102450674B1/ko active Active
- 2016-03-04 WO PCT/NZ2016/050033 patent/WO2016140581A1/en not_active Ceased
-
2020
- 2020-10-23 US US17/078,949 patent/US11938168B2/en active Active
-
2021
- 2021-01-27 JP JP2021011148A patent/JP2021091688A/ja active Pending
-
2023
- 2023-03-01 JP JP2023030945A patent/JP7641650B2/ja active Active
-
2024
- 2024-12-13 JP JP2024218517A patent/JP2025032318A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR102450674B1 (ko) | 2022-10-04 |
| EP3265096B9 (en) | 2023-10-04 |
| WO2016140581A1 (en) | 2016-09-09 |
| EP3265096A4 (en) | 2018-10-24 |
| EP3265096B1 (en) | 2023-06-07 |
| CN107530360A (zh) | 2018-01-02 |
| SG11201708114SA (en) | 2017-11-29 |
| JP2023066425A (ja) | 2023-05-15 |
| US20180050088A1 (en) | 2018-02-22 |
| TWI747816B (zh) | 2021-12-01 |
| JP7641650B2 (ja) | 2025-03-07 |
| US20220047676A1 (en) | 2022-02-17 |
| AU2016226699A1 (en) | 2017-10-26 |
| CN107530360B (zh) | 2021-09-17 |
| US10842850B2 (en) | 2020-11-24 |
| KR20170132197A (ko) | 2017-12-01 |
| JP2018513117A (ja) | 2018-05-24 |
| EP3265096A1 (en) | 2018-01-10 |
| JP2025032318A (ja) | 2025-03-11 |
| JP2021091688A (ja) | 2021-06-17 |
| NZ735959A (en) | 2021-10-29 |
| EP3265096C0 (en) | 2023-06-07 |
| ES2952700T3 (es) | 2023-11-03 |
| US11938168B2 (en) | 2024-03-26 |
| AU2016226699B2 (en) | 2020-10-22 |
| TW201639592A (zh) | 2016-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019003623A (es) | Composiciones y metodos para el tratamiento de afecciones oftalmicas. | |
| MX2022000754A (es) | Composiciones y metodos de uso de nintedanib para tratar enfermedades oculares con neovascularizacion anormal. | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| EP3624773A4 (en) | OPHTHALMIC COMPOSITIONS AND METHOD OF USE | |
| MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
| PH12018500887A1 (en) | Anti-htra1 antibodies and methods of use thereof | |
| EP3177732A4 (en) | Compositions and methods for the treatment of ophthalmic diseases and conditions | |
| EP3687524A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT OF OPHTHALMIC DISORDERS | |
| EP4385521A3 (en) | Storage stable compositions and methods for the treatment of refractive errors of the eye | |
| EP3265096A4 (en) | Ophthalmic compositions and methods of use therefor | |
| EP3429584A4 (en) | COMPOSITIONS AND METHODS FOR TREATING PRESBYOPIA | |
| EP3142664A4 (en) | Compositions and methods for treating and diagnosing ocular disorders | |
| ZA202002066B (en) | Compositions and methods for the treatment of eye disorders | |
| MX2017004808A (es) | Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple. | |
| EP3310353A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF EYE DISEASES | |
| EA201790893A1 (ru) | Способы лечения офтальмологических расстройств | |
| AU2017248276A1 (en) | Methods of treating ocular conditions | |
| EP3618850A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE PATHOLOGIES | |
| GB2541840B (en) | Ophthalmic composition for the treatment of ocular infection | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| GB2564797B (en) | Compositions, kits and methods for maintaining eyelid hygiene | |
| PH12016501434A1 (en) | Compositions for use in the treatment of allergic conditions | |
| EP3265103A4 (en) | Compositions and methods for treating ocular diseases | |
| EP4272761A3 (en) | Compositions for treating ophthalmic conditions | |
| WO2016046759A3 (en) | Compositions and methods for treating friedreich's ataxia |